With the unprecedented scale of the 2014-2016 West Africa outbreak, the clinical and scientific community scrambled to identify potential therapeutics for Ebola virus disease (EVD). Passive administration of antibodies has a long successful history for prophylaxis and therapy of a variety of infectious diseases, but the importance of antibodies in EVD has been unclear and is the subject of some debate. Recent studies in non-human primates have renewed interest in the potential of antibodies to impact EVD. Currently ongoing clinical evaluation of polyclonal and monoclonal antibody therapy in EVD patients in West Africa may finally offer a definitive answer to this debate.
Bibliographical noteFunding Information:
This work was supported by Public Health Agency of Canada (PHAC), the United States Defense Threat Reduction Agency ( HDTRA1-13-C-0018 ), the National Institutes of Health ( U19AI109762 ), and the Biomedical Advanced Research and Development Authority ( HHSO100201400009C ). The contents of the manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies.
© 2016 Elsevier B.V. All rights reserved.